CSIMarket Company Name, Ticker, Industry, else..
 
Virpax Pharmaceuticals Inc   (NASDAQ: VRPX)
 
Price: $0.0111 $0.00 0.000%
Day's High: $0.011099999770522118 Week Perf: 0.00
Day's Low: $ 0.01 30 Day Perf: 11000 %
Volume (M): 0 52 Wk High: $ 0.10
Volume (M$): $ 0 52 Wk Avg: $0.01
Open: $0.01 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 4
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Business Description


Virpax Pharmaceuticals Inc is a pharmaceutical company that focuses on developing and commercializing novel pain management therapies. The company is dedicated to addressing unmet medical needs and enhancing patient outcomes by providing innovative, safe, and effective pain relief solutions. Virpax Pharmaceuticals employs advanced technologies and methodologies to develop and optimize its proprietary drug candidates. The company's goal is to provide patients with non-addictive alternatives to traditional pain management methods, ultimately improving their quality of life.


   Company Address: 1055 Westlakes Drive Berwyn 19312 PA
   Company Phone Number: 727-4597   Stock Exchange / Ticker: NASDAQ VRPX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY   -7.38%    
BMRN   -4.74%    
FOLD        0.21% 
RARE   -0.14%    
REGN   -7.69%    
VRTX   -2.99%    
• View Complete Report
   



Business Update

Virpax Pharmaceuticals A Strategic Step Forward in Non-Addictive Pain Management

Published Thu, Mar 6 2025 6:40 AM UTC

The Dawn of a New Era in Pain Management At the intersection of medical innovation and societal need stands Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a company that has set its sights on pioneering non-addictive treatments for an array of conditions including pain management, post-traumatic stress disorder (PTSD), central nervous system disorders, and viral infections. As...
Business Update

Advancements in Pain Management Virpax Pharmaceuticals Probudur Shows Promise in Swine Model Study Despite Competiti...

Published Mon, Nov 25 2024 12:47 AM UTC

: Virpax Pharmaceuticals, Inc. has made significant strides in the development of Probudur, a long-acting liposomal bupivacaine formulation. Recent results from a dose range finding study conducted in a minipig model indicate potential for effective pain management. However, these advancements come amidst a challenging financial landscape, as the company reported a year-ov...
Business Update

Suggestions1. Virpax Pharmaceuticals Unveils Positive Probudur Study Outcomes Amid Revenue Challenges2. Vir...

Published Sat, Nov 23 2024 2:48 AM UTC

Virpax Pharmaceuticals Announces Encouraging Results for Probudur Amidst Financial Challenges BERWYN, Pa. In a significant step towards advancing its innovative product pipeline, Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced positive outcomes from a Dose Range Finding (DRF) study conducted on Probudur, a long-acting liposomal bupivacaine formulation. This com...
Business Update

Virpax Pharmaceuticals Advances Pain Management Innovation Positive Results from Probudur Dose Range Finding Stu...

Published Fri, Nov 22 2024 1:47 PM UTC

In a significant stride toward innovative pain management solutions, Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a corporation dedicated to developing non-addictive therapeutic options for a variety of conditions including pain management, post-traumatic stress disorder (PTSD), and central nervous system (CNS) disorders, has unveiled encouraging findings from a minipig Dose...
Business Update

Virpax Strengthens its Commitment to Pain Management Solutions with Extended Collaboration with U.S. Health Agencies

Published Thu, Nov 21 2024 10:47 PM UTC

In a significant advancement for pain management, Virpax Pharmaceuticals Inc. (Nasdaq: VRPX) has announced the extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), a distinguished entity of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. This stra...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.61
Working Capital Ratio 0.63
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.05 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.36 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,413,445
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.